RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939
This study is recruiting at 14 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HER2-positive Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2/3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hoffmann-La Roche
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Clearview Cancer Institute · Huntsville, AL
Arizona · 1
- Banner Health MD Anderson AZ · Gilbert, AZ
California · 1
- UCSF Helen Diller Family CCC · San Francisco, CA
Connecticut · 1
- Eastern Connecticut Hematology and Oncology Associates · Norwich, CT
New Jersey · 1
- Astera Cancer Care East Brunswick · East Brunswick, NJ
New York · 4
- New York Oncology Hematology, P.C. · Albany, NY
- New York Cancer and Blood Specialists · Shirley, NY
- Stony Brook Univ Cancer Ctr · Stony Brook, NY
- Montefiore Einstein Cancer Center · The Bronx, NY
Tennessee · 3
- The West Clinic, PC dba West Cancer Center · Germantown, TN
- Sarah Cannon Research Institute · Nashville, TN
- Tennessee Oncology Elliston Place Plaza · Nashville, TN
Texas · 2
- Texas Oncology Cancer Center · Austin, TX
- The Center for Cancer and Blood Disorders - Fort Worth · Fort Worth, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.